Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

https://www.news-medical.net/news/20260529/Targeted-therapy-sunvozertinib-outperforms-standard-chemotherapy-in-advanced-lung-cancer-trial.aspx The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.